Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Digestive Diseases and Sciences
Published in: Digestive Diseases and Sciences 8/2008

01-08-2008 | Original Paper

Signal Transduction Proteins in Tumors From Puerto Rican and Caucasian Gastric Adenocarcinoma Patients: Expression Differences With Potential for Specific Targeted Therapies

Authors: José Cangiano, Barbara A. Centeno, Christopher R. Garrett, William Cáceres, Ana de Jesús, Ji-Hyun Lee, Orestes Pavía, Richard Jove, Luis Báez, Daniel M. Sullivan, Carlos A. Muro-Cacho, Teresita Muñoz-Antonia

Published in: Digestive Diseases and Sciences | Issue 8/2008

Login to get access

Abstract

Overexpression of the HER2/NEU gene is associated with aggressive behavior and poor prognosis in breast cancer, making the Her2/neu protein a directed-therapy target. Tumors of two Puerto Rican (PR) patients overexpressed Her2/neu and resulting partial clinical responses motivated us to compare Her2/neu expression in PR (n = 101) and Caucasian non-Hispanic (n = 95) patients. Immunohistochemistry of tumors showed overexpression of p-Stat3, Cyclin D1, and Her2/neu, compared to non-neoplastic mucosa. Her2/neu and EGF-R protein levels were statistically significantly different with higher levels of both proteins in the PR group. Importantly, Her2/neu expression was strong and diffuse in tumors with signet-ring morphology, while other histo-pathological subtypes showed higher intra-tumoral Her2/neu heterogeneity than typically observed in breast cancer. Targeted therapies in gastric cancer directed at EGF-R and Hers-2/neu pathways warrant further investigation. These therapies may be especially effective in PR patients and in patients with signet-ring cell morphologies with a dismal prognosis.
Literature
1.
Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E, Feuer EJ, Thun MJ (2004) Cancer statistics, 2004. CA Cancer J Clin 54:8–29PubMedCrossRef
2.
Bosetti C, Malvezzi M, Chatenoud L, Negri E, Levi F, La Vecchia C (2005) Trends in cancer mortality in the Americas, 1970–2000. Ann Oncol 16:489–511PubMedCrossRef
3.
Ramirez RR (2004) We the people: Hispanics in the United States, census 2000 special reports. US Census Bureau, Washington, DC
4.
Rosenwaike I, Shai D (1986) Trends in cancer mortality among Puerto Rican-born migrants to New York City. Int J Epidemiol 15:30–35PubMedCrossRef
5.
Menendez-Bergad B, Blum S (1989) Stomach cancer in a native and migrant population in Puerto Rico and New York City, 1975–1979. Bol Asoc Med P R 81:95–98PubMed
6.
Monk M, Warshauer ME (1975) Stomach and colon cancer mortality among Puerto Ricans in New York City and Puerto Rico. J Chronic Dis 28:349–358PubMedCrossRef
7.
Warshauer ME, Silverman DT, Schottenfeld D, Pollack ES (1986) Stomach and colorectal cancers in Puerto Rican-born residents of New York City. J Natl Cancer Inst 76:591–595PubMed
8.
Lores ME, Sorrentino R, Vallecillo L, Rossello PJ (1980) Carcinoma of the stomach: experience at the University Hospital. Bol Asoc Med P R 72:290–297PubMed
9.
Yao JC, Tseng JF, Worah S, Hess KR, Mansfield PF, Crane CH, Schnirer II, Reddy S, Chiang SS, Najam A, Yu C, Giacco GG, Xie K, Wu TT, Feig BW, Pisters PW, Ajani JA (2005) Clinicopathologic behavior of gastric adenocarcinoma in Hispanic patients: analysis of a single institution’s experience over 15 years. J Clin Oncol 23:3094–3103PubMedCrossRef
10.
Yao JC, Schnirer II, Reddy S, Chiang S, Najam A, Yu C, Giacco G, Hess K, Rashid A, Xie K, Lynch P, Ajani JA (2002) Effects of sex and racial/ethnic group on the pattern of gastric cancer localization. Gastric Cancer 5:208–212PubMedCrossRef
11.
Cullinan SA, Moertel CG, Wieand HS, O’Connell MJ, Poon MA, Krook JE, Mailliard JA, Tschetter LK (1994) Controlled evaluation of three drug combination regimens versus fluorouracil alone for the therapy of advanced gastric cancer. North Central Cancer Treatment Group. J Clin Oncol 12:412–416PubMed
12.
Hinoda Y, Sasaki S, Ishida T, Imai K (2004) Monoclonal antibodies as effective therapeutic agents for solid tumors. Cancer Sci 95:621–625PubMedCrossRef
13.
Yoshida T, Sakamoto H, Terada M (1993) Amplified genes in cancer in upper digestive tract. Semin Cancer Biol 4:33–40PubMed
14.
Bhargava R, Gerald WL, Li AR, Pan Q, Lal P, Ladanyi M, Chen B (2005) EGFR gene amplification in breast cancer: correlation with epidermal growth factor receptor mRNA and protein expression and HER-2 status and absence of EGFR-activating mutations. Mod Pathol 18:1027–1033PubMedCrossRef
15.
Ross JS, McKenna BJ (2001) The HER-2/neu oncogene in tumors of the gastrointestinal tract. Cancer Invest 19:554–568PubMedCrossRef
16.
Vizoso FJ, Corte MD, Alvarez A, Garcia I, del Casar JM, Bongera M, Gonzalez LO, Garcia-Muniz JL, Allende MT (2004) Membranous levels of c-erbB-2 oncoprotein in gastric cancer: their relationship with clinicopathological parameters and their prognostic significance. Int J Biol Markers 19:268–274PubMed
17.
Kono K, Naganuma H, Sekikawa T, Amemiya H, Takahashi A, Iizuka H, Matsumoto Y (2000) Serum level of HER-2/neu in patients with gastric cancer: correlation with HER-2/neu overexpression in gastric carcinoma tissue. Tumour Biol 21:139–144PubMedCrossRef
18.
Oshima CT, Lanzoni VP, Iriya K, Forones NM (2001) C-erbB-2 oncoprotein in gastric carcinoma: correlation with clinical stage and prognosis. Int J Biol Markers 16:250–254PubMed
19.
Tanner M, Hollmen M, Junttila TT, Kapanen AI, Tommola S, Soini Y, Helin H, Salo J, Joensuu H, Sihvo E, Elenius K, Isola J (2005) Amplification of HER-2 in gastric carcinoma: association with Topoisomerase II alpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Oncol 16:273–278PubMedCrossRef
20.
Allgayer H, Babic R, Gruetzner KU, Tarabichi A, Schildberg FW, Heiss MM (2000) c-erbB-2 is of independent prognostic relevance in gastric cancer and is associated with the expression of tumor-associated protease systems. J Clin Oncol 18:2201–2209PubMed
21.
Sanz-Ortega J, Steinberg SM, Moro E, Saez M, Lopez JA, Sierra E, Sanz-Esponera J, Merino MJ (2000) Comparative study of tumor angiogenesis and immunohistochemistry for p53, c-ErbB2, c-myc and EGFr as prognostic factors in gastric cancer. Histol Histopathol 15:455–462PubMed
22.
Shida D, Kitayama J, Yamaguchi H, Yamashita H, Mori K, Watanabe T, Nagawa H (2005) Lysophospholipids transactivate HER2/neu (erbB-2) in human gastric cancer cells. Biochem Biophys Res Commun 327:907–914PubMedCrossRef
23.
Kimura M, Tsuda H, Morita D, Shinto E, Tanimoto T, Ichikura T, Mochizuki H, Matsubara O (2005) Usefulness and limitation of multiple endoscopic biopsy sampling for epidermal growth factor receptor and c-erbB-2 testing in patients with gastric adenocarcinoma. Jpn J Clin Oncol 35:324–331PubMedCrossRef
24.
Garcia I, Vizoso F, Andicoechea A, Fernandez P, Suarez C, Garcia-Munz JL, Allende MT (2000) C-erbB-2 oncoprotein content in gastric cancer and in adjacent mucosa. Int J Biol Markers 15:231–234PubMed
25.
Ougolkov A, Mai M, Takahashi Y, Omote K, Bilim V, Shimizu A, Minamoto T (2000) Altered expression of beta-catenin and c-erbB-2 in early gastric cancer. J Exp Clin Cancer Res 19:349–355PubMed
26.
Diaz N, Minton S, Cox C, Bowman T, Gritsko T, Garcia R, Eweis I, Wloch M, Livingston S, Seijo E, Cantor A, Lee J-H, Beam CA, Sullivan D, Jove R, Muro-Cacho C (2006) Activation of stat3 in primary tumors from high-risk breast cancer patients is associated with elevated levels of activated Src and survivin expression. Clin Cancer Res 12:20–28PubMedCrossRef
27.
Moiseyenko VM, Ajani JA, Tjulandin SA, Majlis A, Constenla M, Boni C, Anelli A, Yver AJ, Van Cutsem E (2005) Final results of a randomized controlled phase III trial (TAX 325) comparing docetaxel (T) combined with cisplatin (C) and 5-fluorouracil (F) to CF in patients (pts) with metastatic gastric adenocarcinoma (MGC) [on behalf of the TAX 325 Study Group]. In: Proceedings of the 2005 ASCO annual meeting, Orlando, FL, USA
28.
Kubo A, Corley DA (2004) Marked multi-ethnic variation of esophageal and gastric cardia carcinomas within the United States. Am J Gastroenterol 99:582–588PubMedCrossRef
29.
El-Serag HB, Sonnenberg A (1999) Ethnic variations in the occurrence of gastroesophageal cancers. J Clin Gastroenterol 28:135–139PubMedCrossRef
30.
Wanebo HJ, Kennedy BJ, Chmiel J, Steele G Jr, Winchester D, Osteen R (1993) Cancer of the stomach. A patient care study by the American College of Surgeons. Ann Surg 218:583–592PubMedCrossRef
31.
Correa P (1985) Clinical implications of recent developments in gastric cancer pathology and epidemiology. Semin Oncol 12:2–10PubMed
32.
Schwarz RE, Zagala-Nevarez K (2002) Ethnic survival differences after gastrectomy for gastric cancer are better explained by factors specific for disease location and individual patient comorbidity. Eur J Surg Oncol 28:214–219PubMedCrossRef
33.
Nishigaki R, Osaki M, Hiratsuka M, Toda T, Murakami K, Jeang KT, Ito H, Inoue T, Oshimura M (2005) Proteomic identification of differentially-expressed genes in human gastric carcinomas. Proteomics 5:3205–3213PubMedCrossRef
34.
Kountouras J, Zavos C, Chatzopoulos D (2005) New concepts of molecular biology on gastric carcinogenesis. Hepatogastroenterology 52:1305–1312PubMed
35.
Keller G, Hofler H, Becker KF (2005) Molecular medicine of gastric adenocarcinomas. Expert Rev Mol Med 7:1–13PubMedCrossRef
36.
De Luca A, Iaquinto G (2004) Helicobacter pylori and gastric diseases: a dangerous association. Cancer Lett 213:1–10PubMedCrossRef
37.
Scartozzi M, Galizia E, Freddari F, Berardi R, Cellerino R, Cascinu S (2004) Molecular biology of sporadic gastric cancer: prognostic indicators and novel therapeutic approaches. Cancer Treat Rev 30:451–459PubMedCrossRef
38.
Myllykangas S, Monni O, Nagy B, Rautelin H, Knuutila S (2004) Helicobacter pylori infection activates FOS and stress-response genes and alters expression of genes in gastric cancer-specific loci. Genes Chromosomes Cancer 40:334–341PubMedCrossRef
39.
Wang J, Chi DS, Kalin GB, Sosinski C, Miller LE, Burja I, Thomas E (2002) Helicobacter pylori infection and oncogene expressions in gastric carcinoma and its precursor lesions. Dig Dis Sci 47:107–113PubMedCrossRef
40.
Schneider BG, Hilsenbeck SG, Hensel CH, Pekkel V, Shelton CH, Rodriguez-Martinez HA, Gutierrez-Diaz ME, Pulitzer DR, Allred DC (1994) p53 mutations in gastric and colorectal cancers in Texas Hispanics versus Anglos. Virchows Arch 424:187–193PubMedCrossRef
41.
Morales TG, Sampliner RE, Camargo E, Marquis S, Garewal HS, Fennerty MB (2001) Inability to noninvasively diagnose gastric intestinal metaplasia in Hispanics or reverse the lesion with Helicobacter pylori eradication. J Clin Gastroenterol 32:400–404PubMedCrossRef
42.
Alexander GA, Brawley OW (2000) Association of Helicobacter pylori infection with gastric cancer. Mil Med 165:21–27PubMed
43.
Cangiano JA, Muro-Cacho C, Antonia T, Caceres W, Pavia O, Baez L (2003) Overexpression of the HER2/NEU gene in human gastric adenocarcinoma in Hispanics. In: Proceedings of the American Society of Clinical Oncology, 22:A-3457
44.
Kimura M, Tsuda H, Morita D, Ichikura T, Ogata S, Aida S, Yoshizumi Y, Maehara T, Mochizuki H, Matsubara O (2004) A proposal for diagnostically meaningful criteria to classify increased epidermal growth factor receptor and c-erbB-2 gene copy numbers in gastric carcinoma, based on correlation of fluorescence in situ hybridization and immunohistochemical measurements. Virchows Arch 445:255–262PubMedCrossRef
45.
Varis A, Zaika A, Puolakkainen P, Nagy B, Madrigal I, Kokkola A, Vayrynen A, Karkkainen P, Moskaluk C, El-Rifai W, Knuutila S (2004) Coamplified and overexpressed genes at ERBB2 locus in gastric cancer. Int J Cancer 109:548–553PubMedCrossRef
46.
Funato T, Kozawa K, Fujimaki S, Miura T, Kaku M (2001) Increased sensitivity to cisplatin in gastric cancer by antisense inhibition of the her-2/neu (c-erbB-2) gene. Chemotherapy 47:297–303PubMedCrossRef
47.
Risio M, De Rosa G, Sarotto I, Casorzo L, Capussotti L, Torchio B, Aglietta M, Chiecchio L (2003) HER2 testing in gastric cancer: molecular morphology and storage time-related changes in archival samples. Int J Oncol 23:1381–1387PubMed
48.
Mizutani T, Onda M, Tokunaga A, Yamanaka N, Sugisaki Y (1993) Relationship of C-erbB-2 protein expression and gene amplification to invasion and metastasis in human gastric cancer. Cancer 72:2083–2088PubMedCrossRef
49.
Tsugawa K, Yonemura Y, Hirono Y, Fushida S, Kaji M, Miwa K, Miyazaki I, Yamamoto H (1998) Amplification of the c-met, c-erbB-2 and epidermal growth factor receptor gene in human gastric cancers: correlation to clinical features. Oncology 55:475–481PubMedCrossRef
50.
Gurel S, Dolar E, Yerci O, Samli B, Ozturk H, Nak SG, Gulten M, Memik F (1999) The relationship between c-erbB-2 oncogene expression and clinicopathological factors in gastric cancer. J Int Med Res 27:74–78PubMed
51.
Bi F, Fan D, Hui H, Wang C, Zhang X (2001) Reversion of the malignant phenotype of gastric cancer cell SGC7901 by c-erbB-2-specific hammerhead ribozyme. Cancer Gene Ther 8:835–842PubMedCrossRef
52.
Fujimoto-Ouchi K, Sekiguchi F, Yasuno H, Moriya Y, Mori K, Tanaka Y (2007) Antitumor activity of trastuzumab in combination with chemotherapy in human gastric cancer xenograft models. Cancer Chemother Pharmacol 59:795–805PubMedCrossRef
53.
Gong SJ, Jin CJ, Rha SY, Chung HC (2004) Growth inhibitory effects of trastuzumab and chemotherapeutic drugs in gastric cancer cell lines. Cancer Lett 214:215–224PubMedCrossRef
54.
Kanta SY, Yamane T, Dobashi Y, Mitsui F, Kono K, Ooi A (2006) Topoisomerase II alpha gene amplification in gastric carcinomas: correlation with the HER2 gene. An immunohistochemical, immunoblotting, and multicolor fluorescence in situ hybridization study. Hum Pathol 37:1333–1343PubMedCrossRef
55.
Park DI, Yun JW, Park JH, Oh SJ, Kim HJ, Cho YK, Sohn CI, Jeon WK, Kim BI, Yoo CH, Son BH, Cho EY, Chae SW, Kim EJ, Sohn JH, Ryu SH, Sepulveda AR (2006) HER-2/neu amplification is an independent prognostic factor in gastric cancer. Dig Dis Sci 51:1371–1379PubMedCrossRef
56.
Yano T, Doi T, Ohtsu A, Boku N, Hashizume K, Nakanishi M, Ochiai A (2006) Comparison of HER2 gene amplification assessed by fluorescence in situ hybridization and HER2 protein expression assessed by immunohistochemistry in gastric cancer. Oncol Rep 15:65–71PubMed
57.
Bizari L, Borim AA, Leite KR, Goncalves FT, Cury PM, Tajara EH, Silva AE (2006) Alterations of the CCND1 and HER-2/neu (ERBB2) proteins in esophageal and gastric cancers. Cancer Genet Cytogenet 165:41–50PubMedCrossRef
58.
Garcia I, del Casar JM, Corte MD, Allende MT, Garcia-Muniz JL, Vizoso F (2003) Epidermal growth factor receptor and c-erbB-2 contents in unresectable (UICC R1 or R2) gastric cancer. Int J Biol Markers 18:200–206PubMed
59.
Takehana T, Kunitomo K, Suzuki S, Kono K, Fujii H, Matsumoto Y, Ooi A (2003) Expression of epidermal growth factor receptor in gastric carcinomas. Clin Gastroenterol Hepatol 1:438–445PubMedCrossRef
Metadata
Title
Signal Transduction Proteins in Tumors From Puerto Rican and Caucasian Gastric Adenocarcinoma Patients: Expression Differences With Potential for Specific Targeted Therapies
Authors
José Cangiano
Barbara A. Centeno
Christopher R. Garrett
William Cáceres
Ana de Jesús
Ji-Hyun Lee
Orestes Pavía
Richard Jove
Luis Báez
Daniel M. Sullivan
Carlos A. Muro-Cacho
Teresita Muñoz-Antonia
Publication date
01-08-2008
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 8/2008
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-007-0118-5

Other articles of this Issue 8/2008

Digestive Diseases and Sciences 8/2008 Go to the issue

Original Paper

Alcohol Dehydrogenase (ADH) Isoenzymes and Aldehyde Dehydrogenase (ALDH) Activity in the Sera of Patients with Pancreatic Cancer

Original Paper

The Effect on Gastric Tone of Gastric Electrical Stimulation with Trains of Short Pulses Varies with Sites and Stimulation Conditions

Original Paper

Predictive Factors for Clinical Improvement with Enterra Gastric Electric Stimulation Treatment for Refractory Gastroparesis

Original Paper

Abberant Crypt Foci – Importance in Colorectal Carcinogenesis and Expression of p53 and mdm2: A Changing Concept

Original Paper

Primary Prevention of Adverse Gastroduodenal Effects from Short-Term Use of Non-Steroidal Anti-Inflammatory Drugs by Omeprazole 20 mg in Healthy Subjects: A Randomized, Double-Blind, Placebo-Controlled Study

Original Paper

Interferon Beta 1a versus Interferon Beta 1a plus Ribavirin for the Treatment of Chronic Hepatitis C in Chinese Patients: A Randomized, Placebo-Controlled Trial
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits